EUVIMEDEUVIMED entdecken
Multizentrische Studie

Two-Year Treatment Outcomes of Simultaneous Intravitreal Dexamethasone and Aflibercept on Diabetic Macular Edema

Tai-Chi Lin, Hsin-Wei Huang, Yu-Chien Chung, Tsui-Kang Hsu, Yi-Ming Huang, Sheng-Chu Chi, Chen-Yu Chao, Po-Chen Tseng

Ophthalmologica · 2026

DOI: 10.1159/000550320 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmologica, 2026. Verfasst von Tai-Chi Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Dexamethasone, Receptors, Vascular Endothelial Growth Factor, Macular Edema. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to report 2-year follow-up data on patients with diabetic macular edema (DME) treated with simultaneous intravitreal dexamethasone (DEX) and aflibercept.

Methods

Multicenter, retrospective analysis of eyes with DME treated with simultaneous DEX implant and aflibercept injection. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to 24 months. The secondary endpoint was the interval of retreatment.

Results

Two-year data were available for 52 of the 76 initially included eyes. Compared to baseline, significant improvements in mean BCVA and CRT were observed at 6, 12, 18, and 24 months. An average of 3.26 ± 1.70 intravitreal treatments was required, with a mean retreatment interval of 10.21 ± 6.35 months throughout the study period.

Conclusion

Simultaneous intravitreal DEX and aflibercept treatment resulted in sustained improvements in both visual and anatomical outcomes over a 24-month period. This combination therapy represents a valid treatment strategy and demonstrates synergistic efficacy in the management of DME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsDexamethasoneReceptors, Vascular Endothelial Growth FactorMacular EdemaDiabetic RetinopathyVisual AcuityMacula LuteaHumansIntravitreal InjectionsRetrospective StudiesFemaleMaleTreatment OutcomeTomography, Optical CoherenceFollow-Up StudiesMiddle AgedGlucocorticoidsTime FactorsAgedDrug Therapy, CombinationFluorescein Angiography

Stichwörter der Autor:innen

AfliberceptCombination therapyDexamethasoneDiabetic macular edema

Substanzen

afliberceptRecombinant Fusion ProteinsDexamethasoneReceptors, Vascular Endothelial Growth FactorGlucocorticoids

Autor:innen und Institutionen

  • Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Ophthalmology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Ophthalmology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan.
  • School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.

Zitieren

APA

Lin, T. C., Huang, H. W., Chung, Y. C., Hsu, T. K., Huang, Y. M., Chi, S. C., Chao, C. Y., & Tseng, P. C. (2026). Two-Year Treatment Outcomes of Simultaneous Intravitreal Dexamethasone and Aflibercept on Diabetic Macular Edema. Ophthalmologica. https://doi.org/10.1159/000550320

Vancouver

Lin TC, Huang HW, Chung YC, Hsu TK, Huang YM, Chi SC, et al. Two-Year Treatment Outcomes of Simultaneous Intravitreal Dexamethasone and Aflibercept on Diabetic Macular Edema. Ophthalmologica. 2026. doi:10.1159/000550320

BibTeX
@article{Lin2026,
  author = {Lin, Tai-Chi and Huang, Hsin-Wei and Chung, Yu-Chien and Hsu, Tsui-Kang and Huang, Yi-Ming and Chi, Sheng-Chu and Chao, Chen-Yu and Tseng, Po-Chen},
  title = {Two-Year Treatment Outcomes of Simultaneous Intravitreal Dexamethasone and Aflibercept on Diabetic Macular Edema},
  journal = {Ophthalmologica},
  year = {2026},
  doi = {10.1159/000550320}
}
Kostenlos starten →